Efficacy and Safety of Programmed Cell Death-1/programmed Cell Death Ligand-1 Inhibitors in Advanced Urothelial Malignancy: A Systematic Review and Meta-analysis

Overview

Journal Indian J Urol

Specialty Urology

Date 2019 Apr 20

PMID 31000914

Authors

Smita Pattanaik

Sumit Dey

Nishant Jaiswal

Rachna Rohilla

Shrawan Kumar Singh

Arup Kumar Mandal

Ravimohan Suryanarayan Mavuduru

Affiliations

Soon will be listed here.

Abstract

Introduction: Programmed cell death-1/programmed cell death ligand-1 (PD-1/PDL-1) inhibitors are the newest class of approved drugs for advanced urothelial cancer (AdUC). This review aims to collate the evidence for their efficacy and safety in various treatment settings.

Methods: Extensive search of databases was performed (updated May 2018) and the protocol was registered on PROSPERO (CRD42017081568). The review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis statement. STATA (v 12) and Revman 5.3.5 were used for data analysis.

Results: Ten nonrandomized, open-label clinical trials were included in this review. PD-1/PD-L1 inhibitors were used as second-line, stand-alone in eight trials and as first-line in cisplatin-ineligible in two trials. Heterogeneity was observed for study design, PDL-1 testing methods, cutoff criterias used and translational markers evaluated. The pooled objective response rate (ORR) was 18.2% (95% confidence interval [CI] 15.1-21.2, = 1785) with PD-1/PDL-1 inhibitors in second-line settings as compared to 12.6% (95% CI 10.3-14.9, = 736) with second-line chemotherapy and 23.7% (95% CI 19.9-27.4, = 489) with PD-1/PDL-1 inhibitors as first-line therapy in cisplatin-ineligible patients. The median progression-free survival and overall survival was similar with PD-1/PD-L1 inhibitors in both second- and first-line treatment settings (1.5-2.9 vs. 2.0-2.7 months and 7.9-18.2 vs. 15.9 months) and second-line chemotherapy (3.3-4.0 months and 7.4-8 months). Odds of achieving ORR was 0.10 (95% CI 0.03-0.31, = 229) in the second-line, stand-alone setting with a combined positive score (CPS) cutoff of 25% and was 0.34 (95% CI 0.19-0.62, = 265) with a CPS cut-off of 10% in first-line setting in the cisplatin-ineligible.

Conclusions: PD-1/PDL-1 inhibitors appear to be promising in the treatment of AdUC and CPS may be a potentially reliable biomarker for predicting response but needs validation. Caution needs to be exercised until more data are available on imAEs and further studies are required to prove their worth as the standard of care.

References

Cree I, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K . PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 2016; 69(2):177-86. DOI: 10.1111/his.12996. View

Madore J, Vilain R, Menzies A, Kakavand H, Wilmott J, Hyman J . PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2014; 28(3):245-53. DOI: 10.1111/pcmr.12340. View

Levy A, Massard C, Soria J, Deutsch E . Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016; 68:156-162. DOI: 10.1016/j.ejca.2016.09.013. View

Tzeng A, Diaz-Montero C, Rayman P, Kim J, Pavicic Jr P, Finke J . Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. Target Oncol. 2018; 13(5):599-609. DOI: 10.1007/s11523-018-0595-9. View

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View

De Santis M, Bellmunt J, Mead G, Kerst J, Leahy M, Maroto P . Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2011; 30(2):191-9. PMC: 3255563. DOI: 10.1200/JCO.2011.37.3571. View

Clark P, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M . NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016; 14(10):1213-1224. PMC: 5379654. DOI: 10.6004/jnccn.2016.0131. View

Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View

Vaughn D, Broome C, Hussain M, Gutheil J, Markowitz A . Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002; 20(4):937-40. DOI: 10.1200/JCO.2002.20.4.937. View

10.

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R . Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018; 36(34):3353-3360. DOI: 10.1200/JCO.18.01148. View

11.

Vilain R, Menzies A, Wilmott J, Kakavand H, Madore J, Guminski A . Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clin Cancer Res. 2017; 23(17):5024-5033. DOI: 10.1158/1078-0432.CCR-16-0698. View

12.

McCaffrey J, Hilton S, Mazumdar M, Sadan S, Kelly W, Scher H . Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15(5):1853-7. DOI: 10.1200/JCO.1997.15.5.1853. View

13.

Hirsch F, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K . PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2016; 12(2):208-222. DOI: 10.1016/j.jtho.2016.11.2228. View

14.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

15.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

16.

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J . Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26):3119-25. PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761. View

17.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

18.

Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A . A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. J Transl Med. 2017; 15(1):150. PMC: 5492401. DOI: 10.1186/s12967-017-1251-3. View

19.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. DOI: 10.1016/S1470-2045(17)30065-7. View

20.

Postow M, Callahan M, Wolchok J . Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974-82. PMC: 4980573. DOI: 10.1200/JCO.2014.59.4358. View